AU2009244500A1 - Protection of normal cells - Google Patents

Protection of normal cells Download PDF

Info

Publication number
AU2009244500A1
AU2009244500A1 AU2009244500A AU2009244500A AU2009244500A1 AU 2009244500 A1 AU2009244500 A1 AU 2009244500A1 AU 2009244500 A AU2009244500 A AU 2009244500A AU 2009244500 A AU2009244500 A AU 2009244500A AU 2009244500 A1 AU2009244500 A1 AU 2009244500A1
Authority
AU
Australia
Prior art keywords
sulindac
epimer
derivatives
damage
structural analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009244500A
Other languages
English (en)
Inventor
Nathan Brot
Herbert Weissbach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHS Pharma Inc
Original Assignee
CHS Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHS Pharma Inc filed Critical CHS Pharma Inc
Publication of AU2009244500A1 publication Critical patent/AU2009244500A1/en
Assigned to CHS PHARMA, INC. reassignment CHS PHARMA, INC. Request for Assignment Assignors: FLORIDA ATLANTIC UNIVERSITY, THE HOSPITAL FOR SPECIAL SURGERY
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2009244500A 2008-05-05 2009-05-04 Protection of normal cells Abandoned AU2009244500A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/115,331 2008-05-05
US12/115,331 US8487128B2 (en) 2002-11-26 2008-05-05 Protection of normal cells
PCT/US2009/042703 WO2009137400A2 (en) 2008-05-05 2009-05-04 Protection of normal cells

Publications (1)

Publication Number Publication Date
AU2009244500A1 true AU2009244500A1 (en) 2009-11-12

Family

ID=41265328

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009244500A Abandoned AU2009244500A1 (en) 2008-05-05 2009-05-04 Protection of normal cells

Country Status (7)

Country Link
US (2) US8487128B2 (https=)
EP (1) EP2282733A4 (https=)
JP (1) JP2011520808A (https=)
CN (1) CN102112124A (https=)
AU (1) AU2009244500A1 (https=)
CA (1) CA2755499A1 (https=)
WO (1) WO2009137400A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8487128B2 (en) * 2002-11-26 2013-07-16 Chs Pharma, Inc. Protection of normal cells
EP4464384A3 (en) 2007-08-17 2025-01-08 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
EP2882426A1 (en) * 2012-08-13 2015-06-17 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical compositions for treatment of cystic fibrosis
BR112015011118B1 (pt) 2012-11-15 2022-12-13 Endocyte, Inc Conjugado; composição farmacêutica; e uso de um conjugado
USRE48077E1 (en) 2013-02-28 2020-07-07 Anida Pharma Inc. Methods of treating ototoxicity
WO2014160702A1 (en) 2013-03-25 2014-10-02 Chs Pharma, Inc. Retinopathy treatment
LT4095130T (lt) 2013-10-18 2024-04-25 Novartis Ag Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti
BR112016010927A2 (pt) 2013-11-14 2017-08-08 Endocyte Inc Conjugado de fórmula
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
JP6735225B2 (ja) * 2015-12-25 2020-08-05 共栄化学工業株式会社 皮膚外用組成物及び経口組成物
US11186534B2 (en) * 2017-03-17 2021-11-30 University Of South Alabama Derivatives of sulindac can protect normal cells against oxidative damage
PL237474B1 (pl) * 2017-05-04 2021-04-19 Wyzsza Szkola Medyczna W Bialymstoku Nowe zastosowanie kwasu 2-[(3Z)-6-fluoro-2-metylo-3-[(4-metylosulfinylofenylo) metylideno]inden-1-ylo] octowego
US12208102B2 (en) 2018-04-17 2025-01-28 Endocyte, Inc. Methods of treating cancer
CN114096264B (zh) 2019-05-20 2025-03-14 因多塞特股份有限公司 制备psma缀合物的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5053429A (en) * 1988-04-08 1991-10-01 The Lithox Corporation, Inc. Treating inflammatory pain with methionine
US5401774A (en) * 1991-03-08 1995-03-28 University Of Arizona Method for treating patients with precancerous lesions by administering substituted sulfonyl idenyl acetic and propionic acids and esters to patients with lesions sensitive to such compounds
US5608067A (en) * 1993-12-09 1997-03-04 Afonso; Adriano 4-substituted pyrazoloquinoline derivatives
US6201028B1 (en) * 1998-12-08 2001-03-13 The Rockefeller University Methods and compositions for prevention and treatment of atherosclerosis and hyperlipidemia with non-steroidal anti-inflammatory drugs
EP1469884A1 (en) * 2002-01-30 2004-10-27 Pharmacia Corporation Aldosterone antagonist and non-steroidal anti-inflammatory agent combination therapy to prevent or treat cardiovascular disorders
US8487128B2 (en) * 2002-11-26 2013-07-16 Chs Pharma, Inc. Protection of normal cells
AU2003298020A1 (en) * 2002-11-26 2004-06-18 Florida Atlantic University Catalytic antioxidants and methods of use
US20090312238A1 (en) 2006-05-03 2009-12-17 Florida Atlantic University Protection Against Oxidative Damage in Cells

Also Published As

Publication number Publication date
EP2282733A2 (en) 2011-02-16
US8871971B2 (en) 2014-10-28
EP2282733A4 (en) 2012-12-12
WO2009137400A2 (en) 2009-11-12
CA2755499A1 (en) 2009-11-12
US20140018429A1 (en) 2014-01-16
US20090326073A1 (en) 2009-12-31
CN102112124A (zh) 2011-06-29
JP2011520808A (ja) 2011-07-21
US8487128B2 (en) 2013-07-16

Similar Documents

Publication Publication Date Title
US8487128B2 (en) Protection of normal cells
JP4160115B2 (ja) 疾患の予防及び治療のための酸化防止剤として有用な合成触媒遊離基スカベンジャー
US20090069428A1 (en) Catalytic antioxidants and methods of use
CN112521305B (zh) 治疗帕金森疾病的新型高穿透力药物及其药物组合物
JP2008538586A (ja) 酸化ストレスに関連する疾患および病気の処置のためのｎ−アセチルシステインアミド（ｎａｃアミド）
FR2753098A1 (fr) Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene
OA10165A (en) Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
JP2004514724A (ja) 環状サレン−金属化合物：疾患の処置及び予防において抗酸化剤として有用な反応性酸素種スカベンジャー
Pinnen et al. Codrugs linking L-dopa and sulfur-containing antioxidants: new pharmacological tools against Parkinson’s disease
WO1996040127A1 (en) Nitroxides as protectors against oxidative stress
Mani et al. Drug-induced oxidative stress and cellular toxicity
EP2010164A1 (en) S-nitrosothiols containing compositions and the use of such compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions
US9012492B2 (en) Apocynin-lipoic acid conjugates and uses thereof
WO2007121545A1 (en) S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions
Mason et al. A biological rationale for the cardiotoxic effects of rofecoxib: comparative analysis with other COX-2 selective agents and NSAids
JP7827801B2 (ja) コハク酸プロドラッグ、コハク酸プロドラッグを含有する組成物、及びその使用
US20030171379A1 (en) Methods of treating, preventing, or inhibiting inflammation with Mactanamide compounds
CN105142400B (zh) 防腐体系
EP4101839A1 (en) Compound and use thereof
HK40110815A (en) Succinate prodrug, compositions containing the succinate prodrug and uses thereof
HK40047839B (en) Novel high penetration drugs and pharmaceutical compositions thereof for treatment of parkinson diseases
HK40072910B (en) Succinate prodrug, compositions containing the succinate prodrug and uses thereof
MASON12 et al. A BIOLOGICAL RATIONALE FOR THE CARDIOTOXIC EFFECTS OF ROFECOXIB
DOXORUBICIN SEARCH FOR TREATMENT STRATEGIES TO ENHANCE THE
MIDDLETON et al. NITRIC OXIDE IN THE PATHOGENESIS OF ULCERATIVE COLITIS AND THE POSSIBLE ROLE OF GUT BACTERIA IN ITS SYNTHESIS

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CHS PHARMA, INC.

Free format text: FORMER APPLICANT(S): THE HOSPITAL FOR SPECIAL SURGERY; FLORIDA ATLANTIC UNIVERSITY

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application